The Role of Dexmedetomidine in Intensive Care

  • R. Rahman West
  • A. Rhodes
  • R. M. Grounds


The US Food and Drug Administration (FDA) first approved dexmedetomidine in December 1999 for use as a continuous infusion in post-operative ventilated patients for up to 24 hours in the intensive care unit (ICU). It is not yet approved in the European Union. Its use is currently being evaluated in a number of different situations: Longer-term use, perioperative care, anesthesia, and postoperative analgesia. This chapter will focus on its potential for intensive care patients.


Intensive Care Unit Intensive Care Unit Patient Respiratory Depression Sedative Agent Alcohol Withdrawal Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bhana N, Goa KL, McClellan KJ (2000) Dexmedetomidine. Drugs 59: 263–268CrossRefPubMedGoogle Scholar
  2. 2.
    Savola J-M, Virtanen R (1991) Central alpha2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine. Eur J Pharmacol 195: 193–199CrossRefPubMedGoogle Scholar
  3. 3.
    Szumita PM, Baroletti SA, Anger KE, Wechsler ME (2007) Sedation and analgesia in the intensive care unit: evaluating the role of dexmedetomidine. Am J Health Syst Pharm 64: 37–44CrossRefPubMedGoogle Scholar
  4. 4.
    Kamibayashi T, Maze M (2000) Clinical uses of alpha2-adrenergic agonists. Anesthesiology 93: 1345–1349CrossRefPubMedGoogle Scholar
  5. 5.
    MacMillan LB, Hein L, Smith MS, et al (1996) Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 273: 801–803CrossRefPubMedGoogle Scholar
  6. 6.
    Venn RM, Karol MD, Grounds RM (2002) Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. Br J Anaesth 88: 669–675CrossRefPubMedGoogle Scholar
  7. 7.
    Maze M, Scarfini C, Cavaliere F (2001) New agents for sedation in the intensive care unit. Crit Care Clin 17: 881–897CrossRefPubMedGoogle Scholar
  8. 8.
    Product information Precedex® (dexmedetomidine). Available at: Accessed Nov 2008Google Scholar
  9. 9.
    Venn RM, Newmann PJ, Grounds RM (2003) A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 29: 201–207PubMedGoogle Scholar
  10. 10.
    Martin E, Ramsay G, Mantz J, Sum-Ping ST (2003) The role of the alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intensive Care Med 18: 29–41CrossRefPubMedGoogle Scholar
  11. 11.
    Bachand R, Scholz J, Pinaud M, et al (1999) The effects of dexmedetomidine in patients in the intensive care setting. Intensive Care Med 25 (Suppl 1): S160 (abst)Google Scholar
  12. 12.
    Martin E, Lehott JJ, Manikis P, Torres L, Cote D, Mooi B (1999) Dexmedetomidine: a novel agent for patients in the intensive care setting. Intensive Care Med 25 (Suppl 1): S160 (abst)Google Scholar
  13. 13.
    Riker RR, Ramsay MAE, Prielipp RA, Jorden VSB (2001) Dexmedetomidine provides effective long-term sedation for intubated ICU patients compared to midazolam: a randomized open-label pilot study. Chest 120: 260s (abst)Google Scholar
  14. 14.
    Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M (2004) Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med 30: 2188–2196CrossRefPubMedGoogle Scholar
  15. 15.
    Richard R, Riker RR, Fraser GL (2005) Adverse events associated with sedatives, analgesics and other drugs that provide patient comfort in the intensive care unit. Pharmacotherapy 25: 8S–18SCrossRefGoogle Scholar
  16. 16.
    Venn RM, Grounds RM (2001) Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth 87: 684–690CrossRefPubMedGoogle Scholar
  17. 17.
    Triltsch AE, Welte M, Von Homeyer P, et al (2002) Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study. Crit Care Med 30: 1007–1014CrossRefPubMedGoogle Scholar
  18. 18.
    Dasta JF, Kane-Gill SL, Durtschi AJ (2004) Comparing dexmedetomidineprescribing patterns and safety in the naturalistic setting versus published data. Ann Pharmacother 38: 1130–1135CrossRefPubMedGoogle Scholar
  19. 19.
    Chrysostomou C, Schmitt C (2008) Dexmedetimidine: sedation, analgesia and beyond. Expert Opin Drug Metab Toxicol 4: 619–627CrossRefPubMedGoogle Scholar
  20. 20.
    Venn RM, Bradshaw CJ, Spencer R, et al (1999) Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 54: 1136–1142CrossRefPubMedGoogle Scholar
  21. 21.
    Herr DL, Sum-Ping ST, England M (2003) ICU sedation after coronary artery bypass surgery: dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothor Vasc Anesth 17: 576–584CrossRefGoogle Scholar
  22. 22.
    Ickeringill M, Shehabi Y, Adamson H, Ruettimann U (2004) Dexmedetomidine infusion without loading dose in surgical patients requiring mechanical ventilation: haemodynamic effects and efficacy. Anaesth Intensive Care 32: 741–745PubMedGoogle Scholar
  23. 23.
    Venn RM, Hell J (2004) Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care 4: 302–308CrossRefGoogle Scholar
  24. 24.
    Corbett SM, Rebuck JA, Greene CM, et al (2005) Dexmedetomidine does not improve patient satisfaction when compared to propofol during mechanical ventilation. Crit Care Med 33: 940–945CrossRefPubMedGoogle Scholar
  25. 25.
    Elbaradie S, El Mahalawy FH, Solyman AH (2004) Dexmedetomidine vs propofol for short-term sedation of postoperative mechanically ventilated patients. J Egyptian Nat Cancer Inst 16: 153–158Google Scholar
  26. 26.
    MacLaren R, Forrest LK, Kiser TH (2007) Adjunctive dexmedetomidine therapy in the intensive care unit: a retrospective assessment of impact on sedative and analgesic requirements, levels of sedation and analgesia, and ventilatory and hemodynamic parameters. Pharmacotherapy 27: 351–359CrossRefPubMedGoogle Scholar
  27. 27.
    Arain Sr, Ruehlow RM, Uhrich TD, et al (2004) The efficacy of dexmedetomidine versus morphine for postoperative analgesia after major inpatient surgery. Anesth Analg 98: 153–158CrossRefPubMedGoogle Scholar
  28. 28.
    Hsu YW, Cortinez LI, Robertson KM, et al (2004) Dexmedetomidine pharmacodynamics. Part 1: Crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology 101: 1066–1076CrossRefPubMedGoogle Scholar
  29. 29.
    Ely EW, Shintani A, Truman B, et al (2004) Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 291: 1753–1762CrossRefPubMedGoogle Scholar
  30. 30.
    Maldonado JR, Wysong A, Van Der Starre PJ, et al (2005) Alpha-2 agonist induced sedation prevents ICU delirium in post-cardiotomy patients. J Psychosom Res 58: 61 (abst)CrossRefGoogle Scholar
  31. 31.
    Pandharipande PP, Pun BT, Herr DL, Maze M (2007) Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients. JAMA 298: 2644–2653CrossRefPubMedGoogle Scholar
  32. 32.
    Siobal MS, Kallet RH, Kivett VA, Tang JF (2006) Use of dexmedetomidine to facilitate extubation in surgical intensive-care-unit patients who failed previous weaning attempts following prolonged mechanical ventilation: a pilot study. Respir Care 51: 492–496PubMedGoogle Scholar
  33. 33.
    Baddigam K, Russo P, Russo J, Tobias JD (2005) Dexmedetomidine in the treatment of with-drawal syndromes in cardiothoracic surgery patients. J Intensive Care Med 20: 118–123CrossRefPubMedGoogle Scholar
  34. 34.
    Maccioli GA (2003) Dexmedetomidine to facilitate drug withdrawal. Anesthesiology 98: 575–577CrossRefPubMedGoogle Scholar
  35. 35.
    Multz AS (2003) Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal. Anesth Analg 96: 1054–1055CrossRefPubMedGoogle Scholar
  36. 36.
    Doufas AG, Lin CM, Suleman MI, et al (2003) Dexmedetomidine and meperidine additively reduce the shivering threshold in humans. Stroke 34: 1218–1223CrossRefPubMedGoogle Scholar
  37. 37.
    Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD (2000) The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 93: 382–394CrossRefPubMedGoogle Scholar
  38. 38.
    Paris A, Tonner PH (2005) Dexmedetomidine in anaesthesia. Curr Opin Anaesthesiol 18: 412–418CrossRefPubMedGoogle Scholar
  39. 39.
    Ingersoll-Weng E, Manecke GR Jr, Thistlethwaite PA (2004) Dexmedetomidine and cardiac arrest. Anesthesiology 100: 738–739CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • R. Rahman West
    • 1
  • A. Rhodes
    • 1
  • R. M. Grounds
    • 2
  1. 1.Department of Intensive CareSt George’s HospitalLondonUK
  2. 2.Department of Anesthesiology and Intensive CareFriedrich-Schiller-UniversityJenaGermany

Personalised recommendations